Please note that the details of this Challenge are no longer open. This challenge is awarded and is no longer accepting new submissions. You can:
Challenge Cleveland Clinic: Early Detection of Inflammatory Bowel Disease
Cleveland Clinic: Early Detection of Inflammatory Bowel Disease
STATUS: Awarded
Active Solvers: 317
Posted: Sep 26 2013
Challenge ID: 9933158
 
Team Project Rooms are available on this Challenge Team Share Challenge Share
Abstract

Chronic inflammation is a hallmark of the majority of diseases affecting humanity today, including atherosclerosis, multiple sclerosis, psoriasis, rheumatoid arthritis, asthma, and inflammatory bowel disease. Diagnosis often comes at a point when significant and irreversible damage has already occurred. The challenge is to identify a detection method that will allow for early diagnosis and treatment with sufficient time to adopt lifestyle changes or use agents to prevent or retard disease development. 

This Challenge requires only a written proposal.

 

Overview

In the last fifty years, there has been a steady and marked increase in the incidence and prevalence of chronic inflammatory diseases. This is a problem with far-reaching consequences for patients throughout the world. Inflammatory bowel disease (IBD) with its two main clinical forms (Crohn’s disease and ulcerative colitis) refers to chronic or recurring immune responses and inflammation affecting the gastrointestinal tract. There is no cure and IBD patients require a lifetime of care. Evidence suggests that treatment is more effective when the disease is diagnosed at an early stage. Cleveland Clinic is searching for an accurate early detection system that is based upon the four major IBD contributing factors: environment, genome, immune response, and microbiome. 

Dr. Claudio Fiocchi of the Cleveland Clinic is a physician scientist specializing in gastroenterology and a leader in IBD and mucosal immunity research. Cleveland Clinic strives to make scientific advances that will benefit patient care and support outside relationships that promise public benefit. 

This is a Theoretical Challenge that requires only a written proposal to be submitted.  The Challenge award will be contingent upon theoretical evaluation of the proposal by the Seeker. 

To receive an award, the Solvers must transfer to the Seeker their exclusive Intellectual Property (IP) rights to the solution.  However, the Seeker may be willing to consider a licensing agreement for a partial award if exclusive IP cannot be transferred by the Solver

What is InnoCentive?
InnoCentive is the global innovation marketplace where creative minds solve some of the world's most important problems for cash awards up to $1 million. Commercial, governmental and humanitarian organizations engage with InnoCentive to solve problems that can impact humankind in areas ranging from the environment to medical advancements.

What is a Theoretical IP Transfer Challenge?

An InnoCentive Theoretical Challenge builds upon an idea but is not yet a proof of concept. A solution to a Theoretical Challenge will solidify the Solver's concept with detailed descriptions, specifications and requirements necessary to bringing a good idea closer to becoming an actual product or service.

This Challenge is a Theoretical-IP Transfer Challenge, meaning that Solvers must relinquish all rights to the Intellectual Property (IP) for which they are awarded. By contrast, Theoretical-Licensing means that the Seeker is requesting non-exclusive rights to use the winning solution. For these forms of a Theoretical Challenge, Solvers that do not win retain the rights to their solution after the evaluation period is complete. The Seeker retains no rights to any IP not awarded.

Share This Challenge
InnoCentive Trust Partners